Compare with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES STRIDES PHARMA SCIENCE ALKEM LABORATORIES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 21.9 43.4 50.4% View Chart
P/BV x 5.3 2.0 260.5% View Chart
Dividend Yield % 0.9 0.2 383.2%  

Financials

 ALKEM LABORATORIES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
STRIDES PHARMA SCIENCE
Mar-18
ALKEM LABORATORIES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs2,7201,147 237.1%   
Low Rs1,660642 258.6%   
Sales per share (Unadj.) Rs697.9317.2 220.0%  
Earnings per share (Unadj.) Rs96.17.8 1,225.3%  
Cash flow per share (Unadj.) Rs117.325.1 468.0%  
Dividends per share (Unadj.) Rs25.002.00 1,250.0%  
Dividend yield (eoy) %1.10.2 510.5%  
Book value per share (Unadj.) Rs515.2274.3 187.9%  
Shares outstanding (eoy) m119.5789.50 133.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.8 111.3%   
Avg P/E ratio x22.8114.0 20.0%  
P/CF ratio (eoy) x18.735.7 52.3%  
Price / Book Value ratio x4.33.3 130.3%  
Dividend payout %26.025.5 102.0%   
Avg Mkt Cap Rs m261,87980,058 327.1%   
No. of employees `00014.32.5 571.6%   
Total wages/salary Rs m15,0554,341 346.8%   
Avg. sales/employee Rs Th5,822.611,325.8 51.4%   
Avg. wages/employee Rs Th1,050.51,731.4 60.7%   
Avg. net profit/employee Rs Th802.0280.1 286.4%   
INCOME DATA
Net Sales Rs m83,44428,394 293.9%  
Other income Rs m1,042941 110.8%   
Total revenues Rs m84,48629,334 288.0%   
Gross profit Rs m14,7343,965 371.6%  
Depreciation Rs m2,5281,540 164.1%   
Interest Rs m6511,962 33.2%   
Profit before tax Rs m12,5981,403 897.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,10597 1,135.5%   
Profit after tax Rs m11,493702 1,637.0%  
Gross profit margin %17.714.0 126.4%  
Effective tax rate %8.86.9 126.5%   
Net profit margin %13.82.5 557.0%  
BALANCE SHEET DATA
Current assets Rs m54,96024,836 221.3%   
Current liabilities Rs m32,43318,993 170.8%   
Net working cap to sales %27.020.6 131.2%  
Current ratio x1.71.3 129.6%  
Inventory Days Days8071 112.1%  
Debtors Days Days72113 63.6%  
Net fixed assets Rs m32,71034,289 95.4%   
Share capital Rs m239895 26.7%   
"Free" reserves Rs m61,36823,651 259.5%   
Net worth Rs m61,60724,546 251.0%   
Long term debt Rs m1,59215,513 10.3%   
Total assets Rs m99,43365,437 152.0%  
Interest coverage x20.41.7 1,187.3%   
Debt to equity ratio x00.6 4.1%  
Sales to assets ratio x0.80.4 193.4%   
Return on assets %12.24.1 299.9%  
Return on equity %18.72.9 652.2%  
Return on capital %21.06.9 304.1%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06115,697 102.3%   
Fx outflow Rs m2,483735 337.6%   
Net fx Rs m13,57814,962 90.8%   
CASH FLOW
From Operations Rs m5,8511,871 312.8%  
From Investments Rs m-7,4145,826 -127.3%  
From Financial Activity Rs m792-10,157 -7.8%  
Net Cashflow Rs m-731-2,615 28.0%  

Share Holding

Indian Promoters % 66.9 27.7 241.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 37.8 87.6%  
FIIs % 0.0 8.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 25.9 -  
Shareholders   68,381 56,241 121.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  SUVEN LIFE SCIENCES  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 26, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS